{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/first-class-drugs-journey-market#webpage",
"url": "https://www.fortrea.com/insights/first-class-drugs-journey-market",
"name": "A first-in-class drug's journey to market",
"description": "This Fortrea case study highlights the successful delivery of ophthalmology clinical trials in a rare retinal disease program, demonstrating how strategic execution and close sponsor collaboration supported study performance and delivery. Conducting ophthalmology trials in rare conditions requires specialized site expertise, efficient patient identification, and strong operational coordination to meet study demands. The case study shows how optimized site performance, aligned clinical trial operations, and proactive management approaches enabled consistent execution across participating sites. By strengthening collaboration between sponsor and CRO teams and focusing on efficient study delivery, the approach supported improved timelines and high-quality outcomes. This case study illustrates how tailored strategies in ophthalmology clinical trials can enhance execution, improve site performance, and drive success in complex rare disease clinical development programs."
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "A first-in-class drug's journey to market",
"item": "https://www.fortrea.com/insights/first-class-drugs-journey-market"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry—as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. This commitment is further reinforced by the launch of Fortrea Intelligent Technology, enabling smarter, more connected, and data-driven clinical development. Through Fortrea Intelligent Technology, the organization is advancing data-driven, technology-enabled clinical development to improve speed, quality, and patient outcomes. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/first-class-drugs-journey-market#casestudy",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/first-class-drugs-journey-market#webpage"
},
"headline": "Ophthalmology Clinical Trials in Rare Retinal Disease | Fortrea Case Study",
"description": "This Fortrea case study highlights the successful delivery of ophthalmology clinical trials in a rare retinal disease program, demonstrating how strategic execution and close sponsor collaboration supported study performance and delivery. Conducting ophthalmology trials in rare conditions requires specialized site expertise, efficient patient identification, and strong operational coordination to meet study demands. The case study shows how optimized site performance, aligned clinical trial operations, and proactive management approaches enabled consistent execution across participating sites. By strengthening collaboration between sponsor and CRO teams and focusing on efficient study delivery, the approach supported improved timelines and high-quality outcomes. This case study illustrates how tailored strategies in ophthalmology clinical trials can enhance execution, improve site performance, and drive success in complex rare disease clinical development programs.",
"genre": "Case Study",
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2024-10-15",
"dateModified": "2024-10-15",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2025-01/FINAL_CS_0062_Apellis%20Ophthalmology%20Pharm_1024.pdf",
"encodingFormat": "application/pdf"
}
}
]
}